A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or FOLFOX4 Regimen in Subjects With Advanced Primary Liver Cancer PLC
Phase of Trial: Phase II
Latest Information Update: 18 May 2017
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 May 2017 Status changed from not yet recruiting to recruiting.
- 13 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.
- 31 Mar 2017 New trial record